Literature DB >> 12714513

The coupling of TEL/PDGFbetaR to distinct functional responses is modulated by the presence of cytokine: involvement of mitogen-activated protein kinases.

Helen Wheadon1, Melanie J Welham.   

Abstract

The TEL/PDGFbetaR oncogenic fusion protein is the product of the t(5;12)(q33; p13) translocation recurrently found in patients with chronic myelomonocytic leukemia (CMML). To investigate the coupling of molecular signaling events activated by TEL/PDGFbetaR to functional responses, we expressed TEL/PDGFbetaR in interleukin 3 (IL-3)-dependent BaF/3 cells using the tetracycline-regulated expression system. Induction of TEL/PDGFbetaR expression led to increased cell survival following IL-3 withdrawal and constitutive activation of protein kinase B (PKB), signal transducer and activator of transcription 5 (STAT5), extracellular signal-regulated kinases 1/2 (ERK1/2), Jun N-terminal kinases 1/2 (JNK1/2), and p38 mitogen-activated protein kinase (MAPK) pathways. However, inducible expression of TEL/PDGFbetaR failed to generate factor-independent cells, whereas constitutive expression of TEL/PDGFbetaR did, albeit at low frequency, suggesting the duration of TEL/PDGFbetaR expression is important for transformation. Surprisingly, in cells induced to express TEL/PDGFbetaR, IL-3-dependent growth was dramatically reduced as a result of increased apoptosis of cells receiving combined IL-3 and TEL/PDGFbetaR signals. We demonstrate that TEL/PDGFbetaR expression augmented IL-3-induced activation of PKB, STAT5, ERK1/2, p38, and JNK1/2. Inhibition of neither phosphoinositide-3 kinases nor p38 MAPKs reduced the inhibition of IL-3-driven proliferation observed when TEL/PDGFbetaR was expressed. However, inhibition of MEKs or JNKs partially reversed the combined inhibitory effects of TEL/PDGFbetaR and IL-3 on proliferation and survival. These results suggest that the combination of TEL/PDGFbetaR and IL-3-induced signals activate apoptosis through ERK and JNK MAPK-dependent pathways. Given that in vivo hematopoietic cells are in contact with a variety of cytokines, our results have important implications for cellular responses in the pathogenesis of CMML.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12714513     DOI: 10.1182/blood-2002-09-2974

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.

Authors:  Carmen P Montano-Almendras; Ahmed Essaghir; Hélène Schoemans; Inci Varis; Laura A Noël; Amélie I Velghe; Dominique Latinne; Laurent Knoops; Jean-Baptiste Demoulin
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis.

Authors:  Jean-Baptiste Demoulin; Carmen P Montano-Almendras
Journal:  Am J Blood Res       Date:  2012-01-01

3.  BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.

Authors:  Masahiro Tokunaga; Sachiko Ezoe; Hirokazu Tanaka; Yusuke Satoh; Kentaro Fukushima; Keiko Matsui; Masaru Shibata; Akira Tanimura; Kenji Oritani; Itaru Matsumura; Yuzuru Kanakura
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

4.  Regulation of interleukin-3-induced substrate phosphorylation and cell survival by SHP-2 (Src-homology protein tyrosine phosphatase 2).

Authors:  Helen Wheadon; Christine Edmead; Melanie J Welham
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

5.  Tyrosine kinase chromosomal translocations mediate distinct and overlapping gene regulation events.

Authors:  Hani Kim; Lisa C Gillis; Jordan D Jarvis; Stuart Yang; Kai Huang; Sandy Der; Dwayne L Barber
Journal:  BMC Cancer       Date:  2011-12-28       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.